Genetic profile identification in clinically localized prostate carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 5, 2009, Pages 502-508

  Gallucci, Michele ^a   Merola, Roberta ^a   Leonardo, Costantino ^a   De Carli, Piero ^a   Farsetti, Antonella ^b   Sentinelli, Steno ^a   Sperduti, Isabella ^a   Mottolese, Marcella ^a   Carlini, Paolo ^a   Vico, Erika ^a   Simone, Giuseppe ^a   Cianciulli, AnnaMaria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

Cancer genetics; Chromosomal abnormalities; Prognostic studies; Prostate cancer

Indexed keywords

LIPOPROTEIN LIPASE;

ARTICLE; CANCER GROWTH; CHROMOSOME 7; CHROMOSOME 8; FISH; GENE AMPLIFICATION; GENE DELETION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; X CHROMOSOME;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, X; DISEASE PROGRESSION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOPROTEIN LIPASE; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 69249142732     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.04.008     Document Type: Article

References (28)

1. Partin A., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
2. Das K., Lau W., Sivaswaren C.R., et al. Chromosomal changes in prostate cancer: A fluorescence in situ hybridization study. Clin Genet 68 (2005) 40-47
3. Karan D., Lin M.F., Johansson S.L., et al. Current status of molecular genetics of human prostatic adenocarcinomas. Int J Cancer 103 (2003) 285-293
4. Vocke C.D., Pozzetti R.O., Bostwick D.G., et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p21-22. Cancer Res 56 (1996) 2411-2416
5. Swalwell J.I., Vocke C.D., Yang Y., et al. Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer 33 (2002) 201-205
6. Bethel C.R., Faith D., Li X., et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia and adenocarcinoma: Association with Gleason score and chromosome 8p deletion. Cancer Res 107 (2006) 10683-10690
7. Macoska J., Trybus T., and Wojno K. 8p22 Loss concurrent with 8c gain is associated with poor outcome in prostate cancer. Urology 55 (2000) 776-782
8. Tsuchiya N., Kondo Y., Takahashi A., et al. Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol 160 (2002) 1799-1805
9. Amati B., Alevizopoulos K., and Vlach J. Myc and the cell Cycle. Front Biosci 3 (1998) D250-D268
10. Cui J., Deubler D.A., Rohr L.R., et al. Chromosome 7 abnormalities in prostate cancer detected by dual color FISH. Cancer Genet Cytogenet 107 (1998) 51-60
11. Bandyk M.G., Zhao L., Troncoso P., et al. Trisomy 7, a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 9 (1994) 19-27
12. Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 20 (2002) 3001-3015
13. Ropke A., Erbersdobler A., Hammerer P., et al. Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy. Prostate 59 (2004) 59-68
14. Gallucci M., Merola R., Farsetti A., et al. Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. Cancer Lett 237 (2006) 76-82
15. UICC. TNM Classification of Malignant Tumors. 6h ed. (2002), Wiley-Liss, New York
16. Greenacre M.J. Theory and Applications of Correspondence Analysis (1984), Academic Press, London
17. Lebart L., Morineau A., and Warwick K. Multivariate descriptive statistical analysis (1984), Wiley, New York
18. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after prostatectomy for patients with high risk prostate cancer. J Urol 169 (2003) 157-163
19. Alers J.C., Rochat J., Krijtenburg P.J., et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 80 (2000) 931-942
20. Skacel M., Ormsby A.H., Pettay J.D., et al. Aneusomy of chromosomes 7, 8, and 17, and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma, a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 32 (2001) 1392-1397
21. Tsuchiya N., Slezak J.M., Lieber M.M., et al. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 34 (2002) 363-371
22. Mian C., Lodde M., Comploj E., et al. Molecular biological analysis of the heterogeneous prostate cancer group Gleason Score 7. Prostate 66 (2006) 966-970
23. Strohmeyer D.M., Berger A.P., Moore D.H., et al. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis, association with progression and angiogenesis. Prostate 59 (2004) 43-58
24. Stephenson A.J., Smith A., Kattan M.W., et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104 (2005) 290-298
25. Nanni S., Priolo C., Grasselli A., et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors. A molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 4 (2006) 79-92
26. Glinsky G.V., Glinskii A.B., Stephenson A.J., et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113 (2004) 913-923
27. Mottolese M., Orlandi G., Sperduti I., et al. Biopathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stages I and II breast cancer, identification of an adverse prognostic profile. Am J Surg Pathol 31 (2007) 247-254
28. Gallucci M., Vico E., Merola R., et al. Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer. Exp Mol Pathol 83 (2007) 385-391